Thank you for donating!

You can donate using the following services.


  1. 11.08.19

    Questions from the NPC community regarding the suspension of VTS-270 301 in UK and France (Mallinckrodt)

    Mallinckrodt answer questions from the NPC community regarding the suspension of VTS-270 301 in UK and France...

    Read more
  2. 02.08.19

    Mallinckrodt: official statement regarding the Study 301 suspension

    The following article features a letter regarding the Study 301 Suspension from Sheila Talafous, Director of Advocacy Relations at Mallinckrodt Pharmaceuticals...

    Read more
  3. 26.07.19

    Survey Opportunity: Qualitative Analysis of Niemann-Pick Type C 5-Domain NPCCSS

    We are pleased to inform you of a study opportunity available to NPC patients and their families:
    Clinical Outcomes Solutions (COS), is a research company conducting research into Niemann-Pick type C (NPC) on behalf of a sponsor, Orphazyme A/S, a pharmaceutical company studying NPC...

    Read more
  4. 22.07.19

    Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)

    Following the encouraging regulatory agency feedback, Orphazyme plans to introduce an Early Access
    Program for NPC in the fall of 2019, to further accelerate access to treatment with arimoclomol for people
    living with NPC...

    Read more
  5. 18.07.19

    Anders Hinsby: Letter to NP-C Community

    Anders Hinsby: "I am writing to personally share the news that I will be resigning my position as Orphazyme’s Chief Executive Officer effective October 1, 2019..."

    Read more